Evidence map›Paper›PMID 39113996›Full record

ArticleHeliyon2024

Comparison of Autolumo A2000 Plus and Architect i2000 for detection of hepatitis B virus serological markers.

Xue-Dong Zhang, Xue-Dong Song, Jian-Hua Lu, Yan Dai, Bin Li, Ping Zhu, Er-Hei Dai, Calvin Q Pan, Wei Chen

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Heliyon, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Xue-Dong ZhangDepartment of Clinical Laboratory, the First Affiliated Hospital of Xi'an Jiao Tong University, Xi'an, Shaanxi, China.
Xue-Dong SongHebei Key Laboratory of Immune Mechanism of Major Infectious Diseases and New Technology of Diagnosis and Treatment, The Fifth Hospital of Shijiazhuang, Hebei Medical University, Shijiazhuang, China.
Jian-Hua LuHebei Key Laboratory of Immune Mechanism of Major Infectious Diseases and New Technology of Diagnosis and Treatment, The Fifth Hospital of Shijiazhuang, Hebei Medical University, Shijiazhuang, China.
Yan DaiAutobio Diagnostic Co.Ltd., Zhengzhou, China.
Bin LiAutobio Diagnostic Co.Ltd., Zhengzhou, China.
Ping ZhuDepartment of Laboratory Medicine, the Sixth Hospital of Shijiazhuang, Hebei, China.
Er-Hei DaiHebei Key Laboratory of Immune Mechanism of Major Infectious Diseases and New Technology of Diagnosis and Treatment, The Fifth Hospital of Shijiazhuang, Hebei Medical University, Shijiazhuang, China.
Calvin Q PanCenter of Liver Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, China.
Wei ChenDepartment of Clinical Laboratory, the First Affiliated Hospital of Xi'an Jiao Tong University, Xi'an, Shaanxi, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Serological detection of hepatitis B virus markers plays a vital role in the diagnosis, treatment, prognosis, and therapeutic surveillance of hepatitis B. To compare the diagnostic performance of Autolumo A2000Plus and Abbott Architect i2000 systems in the detection of hepatitis B infection markers. A total of 6 HBV seroconversion panels and 743 participants were enrolled in this study, including 383 HBV-infected patients and 360 healthy adults. Clinical diagnostic information, laboratory results, and HBV genotyping were collected to evaluate the diagnostic performance of the A2000Plus and i2000 systems in detecting HBV infection markers. The results showed that the total percent agreement of HBV markers was all >90 % in both detection systems among the six seroconversion panels and 743 serum samples from the population. The χ2 values of the Chi-square test among hepatitis B virus serological markers in both analyzers were between 550.7 and 743.0,

Indexed as

Abbott Architect i2000 systemsAutolumo A2000Plus systemsDiagnostic performanceHepatitis B infectionLaboratory medicineQuantitative coherence

Identifiers

PMID39113996
PMCPMC11304000

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.